WHAT IS HEALTH ECONOMICS? ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ PHYSICIANS CARE ONLY ABOUT PATIENTS…… PHYSICIANS.

Slides:



Advertisements
Similar presentations
ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
Advertisements

“Concepts in evaluation of vaccination programs in low income countries" Jagrati Jani Section for International Health Department of Community Medicine.
Reducing Need and Demand for Health Care Gero 302 Jan 2011.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Introduction to Pharmacoeconomics
“Rational Pharmacology” and Health Economics By Alan Maynard.
Economic Analysis and Management Todd Wagner, PhD.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Costs.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.
Drug and Therapeutics Committee
Indicators of health and disease frequency measures
Organization of Health Care Services for the Elderly: Russia A.M.Clarfield MD, FRCPC Professor of Gerontology Ben Gurion University, Israel.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
Health system expenditure on disease and injury in Australia: Presentation to OECD Meeting of Health Accounts Experts / Sept 2005 Mr John Goss Principal.
Taxes on the Longevity Dividend: Can we Reduce Them? Lessons from the Theoretical Foundations of Medical Cost-Effectiveness Analysis David Meltzer MD,
Sandip Mitra Central Manchester University Hospitals Foundation Trust.
Web Prevention Early intervention Improved outcomes More effective management of chronic disease.
PHAR 310: Pharmacoeconomics
Health Indicators Mortality indicators Morbidity indicators
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
Health Care Reform April 28 & 29, 2010 Jack A. Lenhart, M.D. Medical Director, Valley Preferred Jack A. Lenhart, M.D. Medical Director, Valley Preferred.
Cost-Effectiveness Thresholds Professor of Health Economics
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
LEVELS OF HEALTH CARE VINITA VANDANA.
Why to study Pharmacoeconomics? Expansion of medical knowledge Increase in the treatment options Burden on the health care professionals to provide effective.
Owen Smith – World Bank Washington DC – February 1 st, 2011 Health care financing in Georgia.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Creating a sporting habit for life. What’s it really worth?: Return on Investment for Physical Activity and Sport Suzanne Gardner Senior Health Manager.
HEALTH A state of complete physical, mental and social well being and not merely the absence of disease or infirmity and ability to lead a socially and.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Health Economic Course Series
Vaccines & Biologicals (V&B) Cost-effectiveness of safe injection policies: Study rationale and proposed methodology Ulla Kou, WHO SIGN meeting in New.
Concepts of Primary health care Ass.Prof:Dr:Essmat Gemaey
Framing a research question Chitra Grace A Scientist- C (PGDHE) NIE, Chennai RM Workshop for ICMR Scientists 01/11/2011.
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
Diabetes and Obesity Journal Club Carina Signori Endocrinology Fellow
100 years of living science Chronic disease management in primary care: lessons to be learnt Dr Shamini Gnani November 2007, Mauritius.
Comparing Australia with Developing Countries Morbidity, life expectancy, infant mortality, adult literacy and immunisation rates can be used to compare.
Supporting Irish patients and the Irish economy Value of Medicines and Vaccines Delivering value to the Irish health services and the Irish economy David.
1 Is it cost-effective to kill patients? Edward Broughton, PhD., MPH Director, USAID Health Care Improvement Project, University Research Co.
Presentation Developed for the Academy of Managed Care Pharmacy
بسم الله الرحمن الرحيم Community Medicine Lec -11-
1 Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID Health Care Improvement Project, University Research Co., LLC
Central American Certificate Course: HIV Monitoring and Evaluation for HIV/AIDS Policy and Program Management BZ ES GT NI PA CR Economic Evaluation and.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
Chapter 14 Economic Analysis of Clinical and Managerial Interventions Copyright 2015 Health Administration Press.
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
Outcomes Measurement in Health
College of Public Health and Human Sciences
WHAT IS HEALTH ECONOMICS?
NAPLEX preparation: Biostatistics
Payment and Funding Mechanisms
Presentation Developed for the Academy of Managed Care Pharmacy
Rita Faria, MSc Centre for Health Economics University of York, UK
Cost-Efficiency of Medication Safety Program at Public Hospital, Riyadh, Saudi Arabia Yousef Ahmed Alomi, Mona Awad Alanazi, Radi Abdullah Alattyh, Fatimah.
Presentation transcript:

WHAT IS HEALTH ECONOMICS? ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ PHYSICIANS CARE ONLY ABOUT PATIENTS…… PHYSICIANS CARE ONLY ABOUT PATIENTS…… HEALTH ECONOMISTS CARE ABOUT RESOURCE$ AND PATIENTS HEALTH ECONOMISTS CARE ABOUT RESOURCE$ AND PATIENTS ECONOMICS IS HOW TO ALLOCATE SCARCE RESOURCES ECONOMICS IS HOW TO ALLOCATE SCARCE RESOURCES

COST-EFFECTIVENESS ANALYSIS (CEA) The cheapest method of attaining the SAME GOAL is the most cost-effective.

CHRONIC RENAL DISEASE (Klareman) HOSP DIALYSIS ($104,000) HOSP DIALYSIS ($104,000) 9 years gained. CPLY=$11,600 HOME DIALYSIS ($38,000) HOME DIALYSIS ($38,000) 9 years gained. CPLY=$4,200 TRANSPLANT ($44,500) TRANSPLANT ($44,500) 17 years gained CPLY=$2,600

BURDEN

Process I 1. Literature search 2. Epi parameters Analysis, review 3. Country data 4. Burden Estimates

BURDEN SCENARIOS

BURDEN SCENARIOS PROGRAM COSTS

BURDEN SCENARIOS VACCINE PROGRAM COSTS DISEASE TREATMENT COSTS

DISEASE TREATMENT COSTS Utilisation Rates for: self-care, self care +medication/herbs, traditional healer, community clinic/GP, in- hospital care, intensive care, out- patient visits. X Unit Costs, including Laboratory tests, Pharmaceuticals and Medications. + COSTS OF DISEASE SEQUELLAE

NET COST PER DALY Net Cost = Cost of Intervention less Averted Treatment Costs Averted Treatment Costs DALYS = sum of life years saved due to decreased mortality + life years saved due to decreased morbidity + reduction in caregiver burden

DALY LOSS PER FRACTURE

COST-UTILITY ANALYSIS PER: LIFE YEAR GAINED LIFE SAVED CASE-PREVENTED NET COST DALY

COST SAVING IF savings in treatment costs > program costs then we can reduce mobidity and mortality AT NO NET COST STRONG PSYCHOLOGICAL PUSH FOR PROGRAMME

VERY COST EFFECTIVE Project considered acceptable in relation to resources available in individual countries Project considered acceptable in relation to resources available in individual countries CPDALY < GNP per head

COST EFFECTIVE Project considered acceptable in relation to resources available in individual countries Project considered acceptable in relation to resources available in individual countries CPDALY < 3 x GNP per head

ALBANIA has $1,120 GNP per Head, CPDALY for HIB=$347 CPDALY < 3 x GNP per head VERY cost-effective if VERY cost-effective if WHO report, says project is cost-effective if WHO report, says project is cost-effective if CPDALY < GNP per head

Disease Clubs Many donors adopt specific diseases, creating jobs and disease clubs, who advocate using burden data, but avoid true comparisons of interventions using CEA. Many donors adopt specific diseases, creating jobs and disease clubs, who advocate using burden data, but avoid true comparisons of interventions using CEA.

INFECTIOUS NCD Good efficacy data, short length of trials Good efficacy data, short length of trials Hard to model herd immunity Hard to model herd immunity Poor efficacy data due to long term needed for results (statins, latency period) Poor efficacy data due to long term needed for results (statins, latency period)

Prevention Programmes Eg: smoking cessation or dietary control Eg: smoking cessation or dietary control Very little population based efficacy data as trials usually were on specific populations such as persons employed in factory etc. Very little population based efficacy data as trials usually were on specific populations such as persons employed in factory etc.

GCEA: THREE PROGRAMME EXAMPLE A = Operation on rare disease (Cost = $1m, QALYS saved = 1) A = Operation on rare disease (Cost = $1m, QALYS saved = 1) B = Operation and drug treatment for rare disease (Cost = $1,001,000, QALYS saved = 2) B = Operation and drug treatment for rare disease (Cost = $1,001,000, QALYS saved = 2) C = Preventive Nutritonal Campaign (Cost = $1,001,000, QALYS= 500) C = Preventive Nutritonal Campaign (Cost = $1,001,000, QALYS= 500)

A B C 1m 0 $ QUALYS A to B, get 1 QALY for $1000 CPQALY = $,1000 Cost = $ 1,001,000 QALY=500 CPQALY= $2,000

INCREMENTAL CEA CHOOSE B SINCE CPQALY = $1,000 cf CHOOSE B SINCE CPQALY = $1,000 cf $2000 for nutrition programme

A B C 1m 0 $ QUALYS CPQ=2,000 CPQ= $500,500 CPQ=$1,000,000

GENERALISED CEA CALCULATE NULL SETTING WHERE NO INTERVENTION OCCURS CALCULATE NULL SETTING WHERE NO INTERVENTION OCCURS CALCULATE ALL INTERVENTIONS WITH RESPECT TO NULL CALCULATE ALL INTERVENTIONS WITH RESPECT TO NULL CHOOSE INTERVENTION C AND GAIN CHOOSE INTERVENTION C AND GAIN = 1998 QALYS

COST per QALY ($)

CEA or CUA CEA or CUA TRANSPARENT, MORE DEMOCRATIC METHOD OF CHOOSING PROGRAMMES THAN BY MARKET, PRESSURE GROUPS, DONOR GROUPS ETC. TRANSPARENT, MORE DEMOCRATIC METHOD OF CHOOSING PROGRAMMES THAN BY MARKET, PRESSURE GROUPS, DONOR GROUPS ETC. BIASED AGAINST ELDERLY AND HANDICAPPED! BIASED AGAINST ELDERLY AND HANDICAPPED! MORE EFFICIENT METHOD IN TERMS OF MAXIMISING HEALTH OUTPUT (DALYS- reflecting mortality and morbidity gains) MORE EFFICIENT METHOD IN TERMS OF MAXIMISING HEALTH OUTPUT (DALYS- reflecting mortality and morbidity gains)

HEALTH ECONOMICS WITHOUT

THANK YOU ………...….…..opportunity cost